Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
The Phillippines (1)
United Kingdom (3)
Vietnam (2)
STADA and certain of its significant subsidiaries have today granted certain in rem security to secure certain capital markets indebtedness …
Peter Goldschmidt has been the new CEO at STADA since September. In this interview he talks about his first time at STADA and his values.
STADA CEO Peter Goldschmidt: "An excellent basis for becoming a key leader in Vietnam"
No pending or expected legal disputes in relation to former members of the Management Board or employees.
STADA wins 2018 Global Generics & Biosimilars Award in “Company of the Year, EMEA” category.
STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG
STADAPHARM GmbH will from now on distribute cytostatic drug Pemetrexed STADA®.
STADA Arzneimittel AG and Ladival GmbH & Co KG have agreed to transfer the rights for the sunscreen Ladival back to the German pharmaceu…
Xbrane Biopharma AB (“Xbrane”) and STADA Arzneimittel AG (“STADA”) have entered into a co-development agreement for Xlucane, a Lucentis® (ra…
STADA is further strengthening its position in branded over-the-counter healthcare products.
STADA continues to advance its strategic reorientation.
STADA has today published the solicitation to the noteholders of the STADA Euro bond 2015/2022.
STADA Arzneimittel AG announced today that the Company’s shareholders approved all agenda items with a large majority that were put to a vot…
STADA is systematically pushing ahead with the new strategy announced in March.
STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange
STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of…
CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology
At the press conference on March 8, 2018 STADA CEO Dr. Claudio Albrecht presented his vision for STADA and the company’s new strategy. In th…
STADA records positive business development in 2017
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a d…
STADA: EMA started the evaluation of resubmitted marketing authorisation application for biosimilar pegfilgrastim
The Extraordinary General Meeting of STADA Arzneimittel AG (STADA) on February 2, 2018 with a majority of 99 percent approved the conclusion…
The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2…
STADA is advancing the internationalization of its OTC brand business.